Centogene AG, Rostock, Germany.
Molecular Medicine Section, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.
Eur J Hum Genet. 2018 Apr;26(4):592-598. doi: 10.1038/s41431-018-0097-3. Epub 2018 Feb 15.
Congenital neurological disorders are genetically highly heterogeneous. Rare forms of hereditary neurological disorders are still difficult to be adequately diagnosed. Pertinent studies, especially when reporting only single families, need independent confirmation. We present three unrelated families in which whole-exome sequencing identified the homozygous non-sense variants c.430[C>T];[C>T] p.(Arg144*), c.1219[C>T];[C>T] p.(Gln407*) and c.1408[C>T];[C>T] p.(Arg470*) in GTPBP2. Their clinical presentations include early onset and apparently non-progressive motor and cognitive impairment, and thereby overlap with findings in a recently described family harbouring a homozygous GTPBP2 splice site variant. Notable differences include structural brain abnormalities (e.g., agenesis of the corpus callosum, exclusive to our patients), and evidence for brain iron accumulation (exclusive to the previously described family). This report confirms pathogenicity of biallelic GTPBP2 inactivation and broadens the phenotypic spectrum. It also underlines that a potential involvement of brain iron accumulation needs clarification. Further patients will have to be identified and characterised in order to fully define the core features of GTPBP2-associated neurological disorder, but future approaches to molecular diagnosis of neurodevelopmental disorders should implement GTPBP2.
先天性神经发育障碍在遗传学上具有高度异质性。罕见形式的遗传性神经发育障碍仍然难以得到充分诊断。相关研究,特别是在仅报告单个家族的情况下,需要独立确认。我们介绍了三个无血缘关系的家族,全外显子组测序在 GTPBP2 中发现了纯合无义变异 c.430[C>T];[C>T] p.(Arg144*)、c.1219[C>T];[C>T] p.(Gln407*)和 c.1408[C>T];[C>T] p.(Arg470*)。他们的临床表现包括早期发病和明显进行性运动和认知障碍,与最近描述的一个携带纯合 GTPBP2 剪接位点变异的家族的发现重叠。显著的差异包括结构性脑异常(例如胼胝体发育不全,仅见于我们的患者)和脑铁积累的证据(仅见于之前描述的家族)。本报告证实了双等位基因 GTPBP2 失活的致病性,并拓宽了表型谱。它还强调了脑铁积累的潜在参与需要澄清。为了全面定义 GTPBP2 相关神经发育障碍的核心特征,还需要进一步识别和表征更多的患者,但未来神经发育障碍的分子诊断方法应实施 GTPBP2。